Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is a promising oncology company with a strong and diverse pipeline, highlighted by its proprietary TTFields technology. The company's recent record revenue quarter and upwardly revised 2026 revenue and expense guidance demonstrate strong execution on the commercial side. The full launch of Optune Pax and the potential for M&A or broader de-risking of TTFields offer upside potential to the company's already successful GBM franchise.

Bears say

NovoCure is facing competition in the lung market, limited treatment duration, and high operating expenses as indicated by their 2Q26 results and 2026 financial estimates, leading to a negative outlook on their stock. Additionally, their growth is heavily reliant on expanding beyond their core GBM franchise and further adoption of their newer products, which may not result in substantial growth.

Novocure (NVCR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 5 analysts, Novocure (NVCR) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.